financetom
Business
financetom
/
Business
/
Greenwich LifeSciences Gets EU Drug Regulator Approval to Add Sites to GLSI-100 Late-Stage Trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Greenwich LifeSciences Gets EU Drug Regulator Approval to Add Sites to GLSI-100 Late-Stage Trial
Jan 29, 2025 6:44 AM

09:18 AM EST, 01/29/2025 (MT Newswires) -- Greenwich LifeSciences ( GLSI ) said Wednesday that the European Medicines Agency has approved its application to add 11 new sites in Spain, Germany, and Poland for a late-stage trial of GLSI-100 to prevent breast cancer recurrences.

The company said that with the latest approval, regulators have cleared the way for the activation of 110 to 115 sites in Europe.

Greenwich said it plans to file applications with the EMA to add 5 to 10 additional sites in Ireland, Romania, and potentially other European countries.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved